Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden

被引：1

作者：

Gong, Jun ^{[1
]}

Patel, Sandip ^{[2
]}

Adashek, Jacob J. ^{[3
]}

Frishberg, David ^{[4
]}

Guan, Michelle ^{[1
]}

Placencio-Hickok, Veronica R. ^{[1
]}

Gangi, Alexandra ^{[5
]}

Gresham, Gillian ^{[1
]}

Tuli, Richard ^{[6
,7
]}

Chae, Young K. ^{[8
]}

Kurzrock, Razelle ^{[2
]}

Hendifar, Andrew E. ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Div Med Oncol, Los Angeles, CA 90048 USA

[2] Univ Calif San Diego, Moores Canc Ctr, Div Hematol Oncol, La Jolla, CA 92093 USA

[3] Western Univ Hlth Sci, Coll Osteopath Med Pacific, Pomona, CA USA

[4] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA

[5] Cedars Sinai Med Ctr, Div Surg Oncol & Hepatobiliary Surg, Dept Surg, Los Angeles, CA 90048 USA

[6] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Radiat Oncol, Los Angeles, CA 90048 USA

[7] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Biomed Sci, Los Angeles, CA 90048 USA

[8] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA

来源：

JCO PRECISION ONCOLOGY | 2020年 / 4卷

基金：

美国国家卫生研究院;

关键词：

CELL LUNG-CANCER; PEMBROLIZUMAB; NIVOLUMAB; IMPACT; PD-L1;

D O I：

10.1200/PO.18.00391

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：514 / 519

页数：6

共 50 条

[1] Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification
Tostes, Francinne T.
Fernandes, Italo
Segatelli, Vanderlei
Callegaro, Donato
Pestana, Roberto Carmagnani
CLINICAL COLORECTAL CANCER, 2021, 20 (04) : 350 - 353
[2] Tumor mutational burden (TMB) and genomic predictors of clinical outcomes to PD-1/PD-L1 checkpoint blockade in high-grade gliomas
Iorgulescu, Bryan
Touat, Mehdi
Li, Yvonne
Spurr, Liam
Grant, Gareth
Pisano, William
Lim-Fat, Mary Jane
Lee, Eudocia
Nayak, Lakshmi
Chiocca, E.
Huang, Raymond
Cherniack, Andrew
Wen, Patrick
Idbaih, Ahmed
Bielle, Franck
Reardon, David
Ligon, Keith
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[3] A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade
Ma, Linlin
Gai, Junwei
Qiao, Peng
Li, Yanfei
Li, Xiaofei
Zhu, Min
Li, Guanghui
Wan, Yakun
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 531 (02) : 144 - 151
[4] Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression
Yang, Xiaobo
Shi, Junping
Chen, Xiaoqian
Jiang, Yan
Zhao, Haitao
ONCOLOGIST, 2020, 25 (06): : 470 - 474
[5] Identification of lncRNA dual targeting PD-L1 and PD-L2 as a novel prognostic predictor for gastric cancer
Zhang, Li-Na
Chen, Jiong-Yu
Liu, Yu-Xin
Zhang, Yue
Hong, Liang-Li
Li, Xin-Xin
Liu, Shu-Hui
Chen, Shu-Qin
Peng, Lin
Huang, Yi-Teng
FRONTIERS IN ONCOLOGY, 2024, 14
[6] Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Zak, Krzysztof M.
Grudnik, Przemyslaw
Magiera, Katarzyna
Domling, Alexander
Dubin, Grzegorz
Holak, Tad A.
STRUCTURE, 2017, 25 (08) : 1163 - 1174
[7] PD-L1 and PD-L2 expression in colorectal cancer
Zeynep, Ozgul
Funda, Canaz
Evrim, Yilmaz
Deniz, Arik
Bulent, Yildiz
Fatih, Yasar. N.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (01) : 31 - 37
[8] LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers
Adashek, Jacob J.
Kato, Shumei
Pabla, Sarabjot
Nesline, Mary
Conroy, Jeffrey M.
Subbiah, Vivek
DePietro, Paul
Kurzrock, Razelle
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies
Thomas, Sean D.
Jeong, Ah-Reum
Sakowski, Patrick J.
Sokol, Ethan S.
Kurzrock, Razelle
Goodman, Aaron M.
BLOOD, 2020, 136
[10] Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy
Peters, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S74 - S74

← 1 2 3 4 5 →